Lessons from the latest Commission decision on agreements affecting generic entry:
- The European Commission’s crack down on so-called “reverse payment” agreements continues.
- In the EU these agreements may...more
12/23/2013
/ Competition ,
Corporate Counsel ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
Fines ,
FTC v Actavis ,
Generic Drugs ,
Johnson & Johnson ,
Novartis ,
Pharmaceutical Industry ,
Reverse Payment Settlement Agreements